Clinical Trials Logo
  1. Home
  2. CRC
  3. NCT05314309

Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening — mtFIT  

CRC Clinical Trial

Official title:
Clinical Validation of a Multi-target Faecal Immunochemical Test (mtFIT) Versus a Faecal Immunochemical Test (FIT) for Detecting Advanced Neoplasia in Population Screening for CRC: a Prospective Cohort Study With Paired Design

Clinical Trial Summary

The primary goal of the population-based colorectal (CRC) screening is early detection and interception of CRC and its precursors to decrease CRC-related morbidity and mortality. To improve current CRC screening programs, the investigators have developed and retrospectively validated a test that combines the detection of multiple proteins in stool (the multitarget faecal immunochemical test, mtFIT). mtFIT was found to have a higher accuracy to detect advanced neoplasia (AN), which includes CRC, advanced adenomas and advanced serrated polyps, in comparison to FIT. Thus, this multitarget test has the potential to improve the screening program's efficiency in reducing CRC-related incidence, morbidity and mortality. This new test, in comparison to FIT, shows specifically higher sensitivity in the detection of advanced adenomas, without affecting specificity.

Clinical Trial Description

Background: The primary goal of population-based CRC screening is early detection and interception of CRC and its precursors to decrease CRC-related morbidity and mortality. New tests, with higher sensitivity for advanced precursor lesions than the current FIT, are desired. The investigators have developed a protein-based multitarget faecal immunochemical test (mtFIT) that shows higher sensitivity for advanced adenomas without losing in specificity. Objective: To prospectively validate the better performance of the mtFIT in comparison to FIT in the setting of a population-based CRC screening program. Material and Methods: In this prospective study, participants of the Dutch National CRC screening program (55-75 years of age) will be invited to participate. Individuals who consent to participate in the study, will be asked to take two stool samples from the same bowel movement. In a central laboratory these two samples then will be analyzed. One with the standard of care faecal immunochemical test (FIT) and the other with the multi-target faecal immunochemical test (mtFIT). If either one of these two tests is positive, individuals will be referred to undergo a colonoscopy procedure. The performance of mtFIT, in comparison to FIT, will be evaluated against the colonoscopy findings. Expected results: mtFIT has higher sensitivity for AN, and in particular advanced adenomas, than FIT, at equal positivity rate. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05314309
Study type Observational
Source The Netherlands Cancer Institute
Contact
Status Active, not recruiting
Phase
Start date March 25, 2022
Completion date May 31, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Active, not recruiting NCT01308086 - Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer Phase 3
Active, not recruiting NCT04585035 - Study to Evaluate D-1553 in Subjects With Solid Tumors Phase 1/Phase 2
Completed NCT03665285 - A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03336658 - Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer
Terminated NCT03875313 - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT05382377 - NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors Early Phase 1
Recruiting NCT06259552 - A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors Phase 1
Completed NCT05976282 - Addressing Colorectal Cancer in South Florida Firefighters N/A
Recruiting NCT01593098 - A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)
Recruiting NCT03597581 - A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer Phase 1
Terminated NCT05368688 - Microbiome in Colorectal Cancer Onset and Progression
Completed NCT03965845 - A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT03601598 - A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC Phase 1/Phase 2
Recruiting NCT05009329 - FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China Phase 1/Phase 2
Completed NCT02161549 - Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy N/A
Active, not recruiting NCT04868773 - Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy Phase 1
Not yet recruiting NCT05239650 - Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC Phase 2